DE102008031038A1 - Use of 2-indolinone derivatives for the treatment of organ transplantation - Google Patents
Use of 2-indolinone derivatives for the treatment of organ transplantation Download PDFInfo
- Publication number
- DE102008031038A1 DE102008031038A1 DE102008031038A DE102008031038A DE102008031038A1 DE 102008031038 A1 DE102008031038 A1 DE 102008031038A1 DE 102008031038 A DE102008031038 A DE 102008031038A DE 102008031038 A DE102008031038 A DE 102008031038A DE 102008031038 A1 DE102008031038 A1 DE 102008031038A1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- organ transplantation
- sutent
- indolinone derivatives
- transplantation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- WINHZLLDWRZWRT-ATVHPVEESA-N CCN(CC)CCNC(c1c(C)[nH]c(/C=C(/c2cc(F)ccc2N2)\C2=O)c1C)=O Chemical compound CCN(CC)CCNC(c1c(C)[nH]c(/C=C(/c2cc(F)ccc2N2)\C2=O)c1C)=O WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transplantation (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Description
Die vorliegende Erfindung betrifft ein neu Anwendung des Medikaments Sutent zur begleitenden Behandlung von Organtransplantationen. Diese Verbindung zeichnet sich durch eine hohe Wirksamkeit zur Verhinderung von Organabstossungen aus.The The present invention relates to a new application of the medicament Sutent for the concomitant treatment of organ transplants. These Compound is characterized by a high effectiveness for prevention from organ rejections.
Organtransplantationen sind haeufig mit Komplikationen verbunden, wie z. B. neurologische Komplikationen, Malignome, Virus oder Bakterien bedingte Infektionen, Entzuendungen, Durchblutungsstoerungen, die zu Amputationen der Extremitaeten fuehren koennen und Abstossungsreaktionen (hyperakut, akut oder chronisch) die zum Tod des Patient fuehren koennen.organ transplants are often associated with complications such. B. neurological Complications, malignancies, virus or bacterial infections, Inflammations, circulatory disturbances leading to amputations of the Extremities can lead to and rejection reactions (hyperacute, acute or chronic) that can lead to the death of the patient.
Sutent ist ein Kinaseinhibitor, der zur Behandlung spezieller Krebsarten eingesetzt wird. Der Wirkmechanismus and die Aktivitaet sind dabei mit der inhibitorischen Wirkung von Sutent gegen Rezeptortyrosinkinasen korreliert.Sutent is a kinase inhibitor used to treat specific cancers is used. The mechanism of action and the activity are included with the inhibitory effect of Sutent on receptor tyrosine kinases correlated.
Aufgabe der vorliegenden Erfindung war die Erweiterung des Wirkbereiches von Kinaseinhibitor Sutent im Bereich der Organtransplantation und damit die neuartige Anwendung von Sutent zur begleitenden Behandlung von Organtransplantationen.task The present invention was the extension of the effective range of kinase inhibitor Sutent in the field of organ transplantation and Thus, the novel application of Sutent for concomitant treatment of organ transplants.
Es wurde gefunden, dass Wirkstoffe der allgemeinen Formel Sutent in Kombination mit in der Transplantationsmedizin ueblichen Medikamenten, eine wesentlich bessere Dosierungsbreite und Anwendungsdauer besitzt und die Zahl der Organabstossungen veringern gegenüber den herkoemmlich eingesetzten Medikamenten und Dosierungen.It It has been found that active ingredients of the general formula Sutent in Combination with drugs commonly used in transplantation medicine, has a much better dosage range and duration of use and the number of organ rejections lower the commonly used drugs and dosages.
Als
Sutentanaloga kommen für die erfindungsgemässe
Verwendung infrage: 2-Indolinonderivate, wie sie in der Patentschrift
Tang,
Peng Cho; Miller, Todd; Li, Xiaoyuan; Sun, Li; Wei, Chung Chen;
Shirazian, Shahrzad; Liang, Congxin; Vojkovsky, Tomas; Nematalla,
Asaad S. Preparation of pyrrole substituted 2-indolinone Protein
kinase inhibitors for treatment of cancer. PCT Int. Appl. (2001),
225 pp.
Tang, Peng Cho; Miller, Todd; Li, Xiaoyuan; Sun, Li; Wei, Chung Chen; Shirazian, Shahrzad; Liang, Congxin; Vojkovsky, Tomas; Nematalla, Asaad S. Preparation of pyrrole substituted 2-indolinone protein kinase inhibitors for treatment of cancer. PCT Int. Appl. (2001), 225 pp.
Bevorzugtes 2-Indolinonderivat für die erfindungsgemässe Verwendung ist Sutent: (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (Sutent)(II) Preferred 2-indolinone derivative for the use according to the invention is sutent: (Z) -N- (2- (diethylamino) ethyl) -5 - ((5-fluoro-2-oxoindolin-3-ylidenes) methyl) -2,4-dimethyl -1H-pyrrole-3-carboxamides (Sutent) (II)
Die genannten Sutentderivate werden in Mengen eingesetzt, die im Bereich der sonst für die Krebsbehandlung üblichen Menge liegen. Die entsprechend vorliegender Erfindung anzuwendende Menge hängt vom Umfang der durch die anderen Medikamente verursachten Nebenwirkungen ab.The said sutine derivatives are used in amounts that are in the range of otherwise for the cancer treatment usual amount. The amount to be used in accordance with the present invention depends on the extent of the side effects caused by the other drugs.
Die erfindungsgemässe Kombination wird vorzugsweise oral verabreicht, infundiert oder intramuskulär injiziert.The combination according to the invention is preferably administered orally, infused or injected intramuscularly.
Eine typische Dosis für die Anwendung am Menschen für den Sutentanteil dieser Erfindung ist, abhängig von der Applikationsart, 10 mg bis 100 mg (i. v.) oder 0,1 mg bis 1000 mg (p. o.), bevorzugt 1 bis 100 mg, besonders bevorzugt 0.05 bis 4 mg/kg Körpergewicht/Minute an x i. v. oder eine biologisch äquivalente Menge eines anderen 2-Indolinonderivates.A typical dose for human use is the Sutentanteil this invention, depending on the Method of administration, 10 mg to 100 mg (i.v.) or 0.1 mg to 1000 mg (p.o.), preferably 1 to 100 mg, more preferably 0.05 to 4 mg / kg body weight / minute at x i. v. or a biologically equivalent Amount of another 2-indolinone derivative.
Die vorliegende Erfindung betrifft somit die neuartige Anwendung von Sutent zur begleitenden Behandlung von Organtransplantationen.The The present invention thus relates to the novel application of Sutent for the concomitant treatment of organ transplants.
Beispielexample
In verscheidenen Versuchen wurden Organe (Leber, Herz, Niere) zwischen Individuen einer Tierspezies (Maus, Ratte, Hamster, Kaninchen, Hund, Schwein) implantive ausgetauscht.In Various attempts were made between organs (liver, heart, kidney) Individuals of an animal species (mouse, rat, hamster, rabbit, dog, Pig) implanted exchanged.
Entsprechende Experimente sind in der Literatur beschrieben:
-
A MODEL OF GRADUAL ONSET BRAIN DEATH FOR TRANSPLANT-ASSOCIATED STUDIES IN RATS1. Transplantation. 69(3): 427–430, February 15, 2000. Pratschke, J. 2 3; Wilhelm, M. J. 2; Kusaka, M. 2 4; Laskowski, I. 2; Tilney, N. L. 2 5 -
Krupnick AS, Kreisel D, Engels FH, Szeto WY, Plappert T, Popma SH, Flake AW, Rosengard BR. A novel small animal model of left ventricular tissue engineering. J Heart Lung Transplant. 2002 Feb; 21(2): 233–43
-
A MODEL OF GRADUAL ONSET BRAIN DEATH FOR TRANSPLANT-ASSOCIATED STUDIES IN RATS1. Transplantation. 69 (3): 427-430, February 15, 2000. Pratschke, J. 2 3; Wilhelm, MJ 2; Kusaka, M. 2 4; Laskowski, I. 2; Tilney, NL 2 5 -
Krupnick AS, Kreisel D, Engels FH, Szeto WY, Plappert T, Popma SH, Flake AW, Rosengard BR. A novel small animal model of left ventricular tissue engineering. J heart lung transplant. 2002 Feb; 21 (2): 233-43
Sutent oder ein biologisch aktives Derivat und andere uebliche Transplantationsmedikamente wurden dabei vor und nach der Transplantation der Organtransplantation den Tieren in verschiedenen Dosiskombinationen verabreicht. Die durchschnittliche Uberlebensdauer der Tiere war statistisch signifikant laenger, im Vergleich zu Sutent unbehandelten Tieren.Sutent or a biologically active derivative and other common transplant medicines were doing before and after the transplantation of organ transplantation administered to the animals in different dose combinations. The average survival of the animals was statistically significant longer, compared to Sutent untreated animals.
ZITATE ENTHALTEN IN DER BESCHREIBUNGQUOTES INCLUDE IN THE DESCRIPTION
Diese Liste der vom Anmelder aufgeführten Dokumente wurde automatisiert erzeugt und ist ausschließlich zur besseren Information des Lesers aufgenommen. Die Liste ist nicht Bestandteil der deutschen Patent- bzw. Gebrauchsmusteranmeldung. Das DPMA übernimmt keinerlei Haftung für etwaige Fehler oder Auslassungen.This list The documents listed by the applicant have been automated generated and is solely for better information recorded by the reader. The list is not part of the German Patent or utility model application. The DPMA takes over no liability for any errors or omissions.
Zitierte PatentliteraturCited patent literature
- - WO 2001060814 A2 [0006] - WO 2001060814 A2 [0006]
Zitierte Nicht-PatentliteraturCited non-patent literature
- - A MODEL OF GRADUAL ONSET BRAIN DEATH FOR TRANSPLANT-ASSOCIATED STUDIES IN RATS1. Transplantation. 69(3): 427–430, February 15, 2000. Pratschke, J. 2 3; Wilhelm, M. J. 2; Kusaka, M. 2 4; Laskowski, I. 2; Tilney, N. L. 2 5 [0013] - A MODEL OF GRADUAL ONSET BRAIN DEATH FOR TRANSPLANT-ASSOCIATED STUDIES IN RATS1. Transplantation. 69 (3): 427-430, February 15, 2000. Pratschke, J. 2 3; Wilhelm, MJ 2; Kusaka, M. 2 4; Laskowski, I. 2; Tilney, NL 2 5 [0013]
- - Krupnick AS, Kreisel D, Engels FH, Szeto WY, Plappert T, Popma SH, Flake AW, Rosengard BR. A novel small animal model of left ventricular tissue engineering. J Heart Lung Transplant. 2002 Feb; 21(2): 233–43 [0013] - Krupnick AS, Kreisel D, Engels FH, Szeto WY, Plappert T, Popma SH, Flake AW, Rosengard BR. A novel small animal model of left ventricular tissue engineering. J heart lung transplant. 2002 Feb; 21 (2): 233-43 [0013]
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008031038A DE102008031038A1 (en) | 2008-06-30 | 2008-06-30 | Use of 2-indolinone derivatives for the treatment of organ transplantation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008031038A DE102008031038A1 (en) | 2008-06-30 | 2008-06-30 | Use of 2-indolinone derivatives for the treatment of organ transplantation |
Publications (1)
Publication Number | Publication Date |
---|---|
DE102008031038A1 true DE102008031038A1 (en) | 2009-12-31 |
Family
ID=41360754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE102008031038A Withdrawn DE102008031038A1 (en) | 2008-06-30 | 2008-06-30 | Use of 2-indolinone derivatives for the treatment of organ transplantation |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE102008031038A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060814A2 (en) | 2000-02-15 | 2001-08-23 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
-
2008
- 2008-06-30 DE DE102008031038A patent/DE102008031038A1/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060814A2 (en) | 2000-02-15 | 2001-08-23 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Non-Patent Citations (2)
Title |
---|
A MODEL OF GRADUAL ONSET BRAIN DEATH FOR TRANSPLANT-ASSOCIATED STUDIES IN RATS1. Transplantation. 69(3): 427-430, February 15, 2000. Pratschke, J. 2 3; Wilhelm, M. J. 2; Kusaka, M. 2 4; Laskowski, I. 2; Tilney, N. L. 2 5 |
Krupnick AS, Kreisel D, Engels FH, Szeto WY, Plappert T, Popma SH, Flake AW, Rosengard BR. A novel small animal model of left ventricular tissue engineering. J Heart Lung Transplant. 2002 Feb; 21(2): 233-43 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0453898B1 (en) | Use of TNF-specific antibodies as a drug for treatment of ischemias and of their consequences | |
AT403122B (en) | THERAPEUTIC INFUSION PREPARATION BASED ON AMINO ACID DERIVATIVES | |
DE60213407T2 (en) | COMPOSITIONS FOR INHIBITING ANGIOGENESIS | |
DE69233643T2 (en) | Use of anticytokin-containing pharmaceutical compositions for the therapy of multiple sclerosis | |
DE2934069C2 (en) | ||
WO1997015300A2 (en) | Use of 4-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for prophylaxis and treatment of sequelae of acute and chronic reduced circulation in the brain and neurodegenerative disorders | |
EP1183047B1 (en) | Pharmaceutical preparation | |
WO1997017084A1 (en) | Drug, in particular for modulating the immunological response for the control of viruses, tumours, bacteria and parasites | |
DE69815788T2 (en) | Use of Des-Aspartate Angiotensin I in the manufacture of a medicament for the prevention and treatment of atherosclerosis, neointima formation and restenosis | |
DE102008031036A1 (en) | Use of 4-aminothiazolpyrimidine derivatives for the treatment of associated organ transplants | |
DE60030567T2 (en) | COMPOSITION COMPRISING MUSCLES DERIVED FROM MUSCLES | |
DE102008031038A1 (en) | Use of 2-indolinone derivatives for the treatment of organ transplantation | |
DE102008031039A1 (en) | Use of N-phenylquinazolin-4-amine derivatives as receptor tyrosine kinase inhibitor for accompanying treatment of organ transplantations | |
DE60203106T2 (en) | AZOLYLCARBYNOL DERIVATIVES OF ARYL (OR HETEROARYL) FOR THE TREATMENT OF RESPIRATORY DISEASES | |
DE19530708C2 (en) | Pharmaceutical preparation with trypanocidal properties | |
DE102008031040A1 (en) | Use of 2-aminopyrimidine derivatives for the treatment of organ transplantation | |
DE2432393C3 (en) | Medicinal preparation for the treatment of malignant neoplasms | |
DE102008031037A1 (en) | Use of 2-aminopyrimidine derivatives as receptor tyrosine kinase inhibitor for accompanying treatment of organ transplantations | |
DE3737274A1 (en) | Use of pure H2A and/or H2B histone as active substance for the production of pharmaceutical compositions | |
DE2163055A1 (en) | Local anesthetic agent | |
DE19953517C1 (en) | Use of treosulfan to condition patients prior to bone marrow transplant or blood stem cell transplant | |
DE60318561T2 (en) | COMBINED TUMOR THERAPY BASED ON DISTAMYCIN-ACRYLOYL DERIVATIVES AND RADIOTHERAPY | |
DE102008031035A1 (en) | Use of urea derivatives as receptor tyrosine kinase inhibitor for accompanying treatment of organ transplantations | |
DE2312134C2 (en) | Anthelmintic | |
DE3707532C2 (en) | Use a combination of Extr. Gingko biloba or at least one gingkolide and acetylsalicylic acid or DL-lysine mono-acetylsalicylate or diflunisal for the treatment of burns, scalds, radiation damage and frostbite |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8139 | Disposal/non-payment of the annual fee |